Deep Vein Thrombosis (DVT): Complete Nursing Notes, Pathophysiology, Management & NORCET MCQs

DEEP VEIN THROMBOSIS (DVT)

Adult Health Nursing | Cardiovascular Disorders | NORCET 12

Complete nursing notes with clinical parameters, diagnostic algorithms, original diagrams, anticoagulant safety, prevention, nursing priorities and 25 case-based MCQs.

Clinical Guidelines Wells Score D-dimer Doppler Ultrasound 30-Minute MCQ Test

Learning Objectives

• Define DVT and explain its pathophysiology.
• Identify Virchow's triad and major risk factors.
• Recognize clinical features and pulmonary embolism warning signs.
• Understand the two-level Wells score for suspected lower-limb DVT.
• Explain the role and limitations of D-dimer and compression ultrasound.
• Describe anticoagulation, nursing care and prevention of venous thromboembolism.
• Apply current guideline-based principles to clinical scenarios.

Table of Contents

1. Definition and Overview
2. Venous Anatomy and Types
3. Virchow's Triad
4. Risk Factors
5. Pathophysiology
6. Clinical Manifestations
7. Pulmonary Embolism: Emergency Recognition
8. Two-Level Wells Score
9. Diagnostic Tests and Parameters
10. Diagnostic Algorithm
11. Medical Management
12. Anticoagulant Drugs
13. Nursing Management
14. Prevention and Patient Education
15. Complications
16. Special Situations
17. Mnemonics and Quick Revision
18. 25 Interactive MCQs
19. Guideline References

1. Definition and Overview

Deep vein thrombosis (DVT) is the formation of a blood clot within a deep vein, most commonly in the lower extremity. It is part of venous thromboembolism (VTE), which includes DVT and pulmonary embolism (PE).

A clot may partially or completely obstruct venous blood flow. A portion of the clot can detach, travel through the venous circulation and right side of the heart, and lodge in the pulmonary arteries, producing a pulmonary embolism.

High-yield distinction:
DVT = thrombus in a deep vein.
PE = obstruction of pulmonary arteries, usually by an embolus originating from a venous thrombus.
VTE = the clinical spectrum that includes DVT and PE.

Why is DVT clinically important?

• It can cause pain and swelling of the affected limb.
• It can lead to pulmonary embolism, which may be life-threatening.
• It may cause long-term venous damage and post-thrombotic syndrome.
• Prompt assessment and appropriate treatment reduce the risk of progression and complications.

2. Venous Anatomy and Types

Lower-limb veins

• Deep veins: include the popliteal, femoral, common femoral and iliac veins, as well as deep calf veins.
• Superficial veins: include the great and small saphenous veins.
• Perforator veins: connect superficial and deep venous systems.

Classification

Type	Description	Clinical significance
Proximal DVT	Thrombus involving the popliteal vein or more proximal veins, depending on the classification used.	Greater risk of clinically significant PE than isolated distal calf DVT.
Distal DVT	Thrombus confined to deep calf veins below the popliteal vein.	May require anticoagulation or structured surveillance depending on symptoms, extension risk and guideline criteria.
Upper-extremity DVT	Thrombus in deep veins of the arm, often associated with central venous catheters or other risk factors.	Can cause arm swelling and can also lead to PE.

3. Virchow's Triad

Virchow's triad describes three major mechanisms that promote thrombosis.

Component	Examples
Venous stasis	Immobility, prolonged bed rest, long travel, paralysis, heart failure.
Endothelial injury	Major surgery, trauma, fractures, venous catheters and some vascular procedures.
Hypercoagulability	Active cancer, pregnancy/postpartum period, estrogen exposure, inherited thrombophilia and some systemic illnesses.

Memory trick: “S-I-C”
Stasis — slow blood flow.
Injury — damage to vessel lining.
Coagulability — increased tendency to clot.

4. Risk Factors

Major risk factors

• Previous DVT or PE.
• Major surgery, especially when followed by immobility.
• Hospital admission, prolonged bed rest or paralysis.
• Fracture or significant trauma.
• Active cancer and some cancer treatments.
• Pregnancy and the postpartum period.
• Estrogen-containing contraceptives or hormone therapy.
• Inherited or acquired thrombophilia.
• Older age, obesity and some chronic illnesses.
• Long periods of sitting or immobility, including prolonged travel.
• Central venous catheters, particularly for upper-extremity DVT.

Risk is often multifactorial. A patient may have several moderate risk factors that together substantially increase the probability of thrombosis.

5. Pathophysiology

1. Venous stasis, vessel-wall injury or hypercoagulability promotes clot formation.
2. A thrombus develops within a deep vein.
3. The clot may obstruct venous return, causing swelling, discomfort and venous pressure elevation.
4. The thrombus may extend into more proximal veins.
5. A portion may detach and travel through the inferior vena cava and right side of the heart into the pulmonary arteries.
6. Pulmonary vascular obstruction may cause impaired oxygenation, right ventricular strain, hemodynamic instability or death.

6. Clinical Manifestations

Common symptoms and signs

• Unilateral leg swelling.
• Pain or tenderness, often in the calf or thigh.
• Increased warmth of the affected limb.
• Redness or discoloration.
• Pitting edema, sometimes greater on one side.
• Prominent superficial collateral veins in some patients.

Important: DVT can be asymptomatic. Symptoms are not specific, and cellulitis, muscle injury, a ruptured Baker cyst and other conditions may mimic DVT. Clinical assessment and appropriate testing are required.

Homan's sign

Homan's sign refers to calf discomfort during passive dorsiflexion of the foot. It is unreliable and should not be used to diagnose or exclude DVT. Avoid forceful calf manipulation or relying on this sign as a screening test.

7. Pulmonary Embolism: Emergency Recognition

Suspect PE in a patient with possible or confirmed DVT who develops new respiratory or cardiovascular symptoms.

Warning signs

• Sudden shortness of breath.
• Pleuritic chest pain or unexplained chest pain.
• Rapid breathing or tachycardia.
• Low oxygen saturation or cyanosis.
• Hemoptysis in some patients.
• Syncope, hypotension, shock or cardiac arrest in severe PE.

Emergency priority: Sudden breathlessness, chest pain, fainting or hemodynamic instability in a patient with suspected DVT requires immediate emergency response. Assess airway, breathing and circulation, monitor oxygen saturation and vital signs, and escalate urgently according to local protocol.

8. Two-Level Wells Score for Suspected Lower-Limb DVT

The two-level Wells score estimates clinical probability. It does not independently confirm or exclude DVT. The following is the adult lower-limb score used in the NICE diagnostic pathway; other protocols may differ.

Clinical feature	Score
Active cancer: treatment ongoing, within the previous 6 months, or palliative	+1
Paralysis, paresis or recent plaster immobilization of the lower extremity	+1
Recently bedridden for at least 3 days, or major surgery within 12 weeks requiring general or regional anesthesia	+1
Localized tenderness along the distribution of the deep venous system	+1
Entire leg swollen	+1
Calf swelling at least 3 cm greater than the asymptomatic side, measured 10 cm below the tibial tuberosity	+1
Pitting edema confined to the symptomatic leg	+1
Collateral superficial veins, not varicose	+1
Previously documented DVT	+1
An alternative diagnosis is at least as likely as DVT	−2

Interpretation

Score ≥2: DVT likely.

Score ≤1: DVT unlikely.

NORCET high-yield: Calf circumference difference of at least 3 cm is one of the Wells criteria. The calf is measured 10 cm below the tibial tuberosity, comparing the symptomatic and asymptomatic sides.

Practice calculation

A patient has unilateral leg swelling (+1), localized deep-vein tenderness (+1), and recent major surgery within 12 weeks (+1). No alternative diagnosis is considered equally likely.

Total Wells score = 3. Under the NICE two-level classification, DVT is likely. This requires the appropriate diagnostic pathway; the score itself does not prove a clot.

9. Diagnostic Tests and Parameters

A. Compression duplex ultrasonography

Ultrasound is the main imaging test for suspected lower-limb DVT. Compression ultrasound evaluates whether a vein can be compressed; a vein that fails to compress normally may indicate thrombus. Duplex techniques also assess blood flow.

• Non-invasive and does not use ionizing radiation.
• Can identify many proximal lower-limb DVTs.
• Accuracy depends on the location of the clot, technique and clinical setting.
• A negative initial proximal ultrasound may require additional testing or repeat imaging when clinical suspicion remains.

B. D-dimer

D-dimer is a fibrin degradation product. It can help exclude DVT in patients with an appropriate low or unlikely pre-test probability when a sufficiently sensitive assay is negative.

Result or situation	Interpretation
Negative D-dimer with low/unlikely pre-test probability	Can help exclude DVT within an appropriate validated pathway.
Positive D-dimer	Does not diagnose DVT; imaging is generally required.
Older age, pregnancy, cancer, infection, inflammation, recent surgery or trauma	May elevate D-dimer and reduce specificity.

Never diagnose DVT from a positive D-dimer alone. D-dimer assays use different reporting units and cutoffs. A value such as 500 ng/mL FEU is a commonly used conventional cutoff in some assays, not a universal cutoff for every laboratory or every patient. Follow the assay reference range and validated pathway.

C. Baseline laboratory tests

• Complete blood count (CBC), including hemoglobin and platelet count.
• Renal function, such as creatinine and eGFR.
• Liver function tests when appropriate.
• PT/INR and APTT according to the anticoagulant and clinical protocol.
• Pregnancy testing when relevant to imaging or medication choices.

These tests help assess bleeding risk, identify contraindications and guide safe anticoagulant selection. They do not independently diagnose DVT.

D. Additional investigations

• CT or MR venography may be considered in selected cases where standard ultrasound is inadequate or an unusual venous site is suspected.
• For suspected PE, CTPA is commonly used when indicated; ventilation/perfusion imaging is an alternative in selected circumstances.
• ECG, chest imaging and blood gas testing may help assess a patient with suspected PE but cannot independently exclude PE.

10. Diagnostic Algorithm

NICE NG158 diagnostic principles:

• For DVT likely (Wells score ≥2), offer proximal leg vein ultrasound promptly, ideally with results within 4 hours when feasible.
• If the scan cannot be obtained within 4 hours, NICE recommends D-dimer testing, interim therapeutic anticoagulation when appropriate, and ultrasound within 24 hours.
• For DVT unlikely (Wells score ≤1), use D-dimer first. If positive, proceed to ultrasound and follow the pathway.
• When interim anticoagulation is used, obtain baseline blood tests but do not delay starting treatment solely while awaiting their results; review results promptly, generally within 24 hours, as directed by the guideline.

11. Medical Management

The treatment plan depends on clot location, symptom severity, bleeding risk, kidney function, pregnancy status, cancer, recurrence risk and the patient's overall condition.

A. Anticoagulation

Anticoagulants reduce clot propagation and the risk of further thromboembolism while the body's natural processes gradually break down the clot. They do not instantly dissolve an existing thrombus.

Common options include direct oral anticoagulants (DOACs), low-molecular-weight heparin (LMWH), unfractionated heparin and vitamin K antagonists in selected circumstances.

B. Duration of treatment

• NICE recommends anticoagulation for at least 3 months for confirmed proximal DVT or PE, unless contraindicated.
• Longer treatment may be considered when recurrence risk is substantial, such as with some unprovoked or recurrent events, persistent risk factors or active cancer.
• For isolated distal DVT, treatment versus serial ultrasound surveillance depends on symptoms, risk of extension and the applicable guideline.
• Decisions about extending therapy must balance recurrence risk against bleeding risk and patient preferences.

C. Other interventions

• Thrombolysis: reserved for selected patients with severe or limb-threatening thrombosis or specific high-risk PE scenarios because of significant bleeding risk.
• Catheter-directed interventions: considered in selected cases by specialist teams.
• Inferior vena cava (IVC) filter: may be considered in specific situations, such as a contraindication to anticoagulation. It is not a routine replacement for anticoagulation.
• Compression therapy: may help selected patients with symptoms; it should be individualized and is not a substitute for anticoagulation when indicated.

Clinical safety: Suspected DVT should be assessed promptly. Do not self-start anticoagulants, massage a suspected thrombosed leg or delay emergency care for PE symptoms. Interim anticoagulation is a clinician-directed decision based on the diagnostic pathway and bleeding risk.

12. Anticoagulant Drugs and Nursing Parameters

Drug/class	Key monitoring	Important nursing points
Unfractionated heparin (UFH)	aPTT or anti-Xa according to protocol; CBC and platelets	Rapid onset; often requires infusion monitoring. Watch for bleeding and heparin-induced thrombocytopenia (HIT).
Low-molecular-weight heparin (e.g., enoxaparin)	CBC, platelets, renal function and bleeding assessment	Subcutaneous administration; dose selection depends on indication, body weight and renal function. Anti-Xa monitoring is used only in selected situations.
Warfarin	PT/INR	Requires INR monitoring and attention to drug/food interactions. Initial treatment for acute VTE usually requires appropriate parenteral overlap according to the protocol.
Apixaban or rivaroxaban	CBC, renal/liver function as appropriate and bleeding assessment	Routine INR monitoring is not used to measure their anticoagulant effect. Dosing and suitability depend on indication and patient factors.
Dabigatran or edoxaban	Renal function, CBC and bleeding assessment	For acute VTE, these agents generally require an initial course of parenteral anticoagulation according to their approved regimen.

Important anticoagulant safety parameters

• Check baseline hemoglobin, platelet count and renal function as appropriate.
• Review active bleeding, recent major bleeding, surgery, falls risk and interacting medicines.
• Assess for hematuria, melena, hematemesis, unexplained bruising, severe headache or neurological changes.
• For warfarin, INR targets depend on the indication and clinical protocol; a common target for VTE treatment is INR 2.0–3.0.
• For UFH, the therapeutic aPTT range is laboratory- and protocol-specific; do not use one universal numerical range.
• Do not monitor DOAC efficacy with routine INR testing.
• Pregnancy, severe renal impairment, active cancer and antiphospholipid syndrome may affect drug choice.

HIT alert: Heparin-induced thrombocytopenia is an immune-mediated reaction that can cause a platelet fall and new thrombosis. If suspected, urgent clinician review and discontinuation of all heparin exposure are required, with alternative anticoagulation managed by the treating team.

13. Nursing Management

A. Assessment

• Assess limb swelling, pain, warmth, color and circumference according to local protocol.
• Record vital signs and oxygen saturation when indicated.
• Ask about previous DVT/PE, recent surgery, immobility, cancer, pregnancy, hormone use and anticoagulant history.
• Assess for bleeding risk before anticoagulation.
• Monitor for new chest pain, dyspnea, tachycardia, hypoxia, syncope or hypotension suggesting PE.

B. Nursing interventions

1. Escalate suspected DVT promptly for clinical evaluation and diagnostic testing.
2. Administer prescribed anticoagulants safely and verify the correct dose, route, timing and renal considerations.
3. Monitor CBC, platelets, renal function, coagulation tests and bleeding symptoms according to the medication and protocol.
4. Measure and document limb findings consistently when requested.
5. Support the affected limb comfortably and elevate it when appropriate for swelling and comfort.
6. Encourage mobility when clinically appropriate and consistent with the treatment plan.
7. Provide clear education about medication adherence, missed doses, bleeding precautions and follow-up.
8. Escalate any sudden respiratory or cardiovascular symptoms immediately.

C. What should the nurse avoid?

• Do not massage the affected leg or repeatedly perform forceful calf maneuvers.
• Do not rely on Homan's sign to diagnose DVT.
• Do not independently discontinue anticoagulation because swelling or pain improves.
• Do not delay emergency assessment when PE is suspected.
• Do not apply compression devices to a limb with suspected or confirmed acute DVT without following the clinical plan and local protocol.

Priority-based question clue: If a patient with known DVT suddenly develops severe breathlessness and chest pain, assess ABCs and activate emergency response. Do not prioritize routine limb measurement or discharge education.

14. Prevention and Patient Education

Hospital prevention

• Assess VTE and bleeding risk on admission and when clinical status changes.
• Encourage early mobilization when safe.
• Use prescribed pharmacological prophylaxis when indicated and not contraindicated.
• Use intermittent pneumatic compression or other mechanical prophylaxis when indicated by the clinical plan.
• Maintain hydration when appropriate and avoid unnecessary immobility.

Home and travel advice

• Take prescribed medicines exactly as directed.
• Move the legs and walk periodically during prolonged sitting when safe.
• Maintain an appropriate activity level after clinical advice.
• Discuss individualized prevention after surgery, during pregnancy or with cancer treatment.
• Seek urgent help for sudden dyspnea, chest pain, coughing blood or fainting.
• Seek prompt assessment for new unilateral leg swelling or pain.

Important: Routine anticoagulant prophylaxis is not necessary for every traveler or every low-risk ambulatory person. Prevention should be individualized to the person's risk factors and bleeding risk.

15. Complications

Complication	Description
Pulmonary embolism	Embolus obstructs pulmonary arteries; may cause respiratory failure, right-heart strain or shock.
Post-thrombotic syndrome	Chronic pain, heaviness, swelling, skin changes and occasionally venous ulcers after DVT.
Recurrent VTE	New DVT or PE after a previous event.
Chronic venous obstruction	Persistent venous hypertension and impaired venous return.
Phlegmasia cerulea dolens	Rare, severe extensive venous thrombosis with marked swelling, cyanosis and threatened limb perfusion; requires emergency specialist care.
Anticoagulant-related bleeding	Potential treatment complication, ranging from minor bleeding to life-threatening hemorrhage.

16. Special Situations

Pregnancy and postpartum period

• Pregnancy and the postpartum period increase VTE risk.
• Assessment and imaging require a pregnancy-specific pathway.
• LMWH is commonly used for treatment of VTE in pregnancy under specialist guidance.
• DOACs are generally avoided during pregnancy and breastfeeding; the treating specialist should select the appropriate regimen.
• Suspected DVT or PE during pregnancy requires prompt assessment and should not be dismissed because symptoms overlap with normal pregnancy.

Cancer-associated thrombosis

Active cancer and some treatments increase VTE risk. Anticoagulant choice must account for cancer type, bleeding risk, kidney function, interactions, procedures and patient preference. Treatment may need to continue beyond the initial period while cancer or other persistent risk factors remain active.

Renal impairment

Renal function affects the choice and dose of several anticoagulants. A patient with significant renal impairment requires clinician-led selection and monitoring; standard doses should not be assumed suitable for everyone.

17. Mnemonics and Quick Revision

Mnemonic: Virchow's Triad — SIC

• S — Stasis.
• I — Injury to vessel lining.
• C — Coagulability increased.

Mnemonic: Suspect DVT — “SWELL”

• S — Swelling, often unilateral.
• W — Warmth or discoloration.
• E — Elevated risk factors such as immobility or surgery.
• L — Localized deep-vein tenderness.
• L — Look for PE symptoms and escalate urgently if present.

High-yield revision table

Exam point	Correct concept
Most common clinical setting	Lower-extremity deep veins
Virchow's triad	Stasis, endothelial injury, hypercoagulability
Common imaging test	Compression duplex ultrasound
Wells score ≥2	DVT likely in the NICE two-level system
Wells score ≤1	DVT unlikely in the NICE two-level system
Calf circumference criterion	At least 3 cm difference, measured 10 cm below tibial tuberosity
D-dimer positive	Not diagnostic; further assessment/imaging is usually needed
Confirmed proximal DVT	Anticoagulation for at least 3 months is generally recommended when appropriate
UFH monitoring	aPTT or anti-Xa per protocol; monitor CBC and platelets
Warfarin monitoring	PT/INR
DOAC monitoring	Clinical assessment, CBC and renal/liver function as appropriate; INR does not measure DOAC effect
Sudden dyspnea and chest pain	Suspect PE and initiate emergency response
Homan's sign	Unreliable; not used to diagnose or exclude DVT

18. NORCET 12 Interactive Test — 25 MCQs

DVT: Clinical, Diagnostic and Priority-Based Questions
Question 1 of 25

Time: 30:00

Instructions: Select one best answer. Use Previous and Next to navigate. Each correct answer carries 1 mark. Submit to view your score and explanations.

19. Guideline References and Further Reading

• NICE NG158 — Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing recommendations.
• American Society of Hematology: VTE diagnosis guidelines.
• American Society of Hematology: DVT and PE treatment guidelines.
• Adult VTE guideline, University of Michigan, 2024: Adult Venous Thromboembolism Guideline.

Guideline update note: NICE NG158 was last updated on 2 August 2023 and was reviewed on 1 May 2026, when NICE stated it would not be updating the guideline to include recommendations on early mobilization or bed rest. Diagnostic pathways and anticoagulant choices may differ across countries and clinical settings. Use current local protocols for patient care.

Educational disclaimer: These notes are for nursing education and examination preparation, not a substitute for clinical assessment. Suspected DVT or PE requires prompt professional evaluation. Anticoagulants can cause serious bleeding and must be prescribed and monitored according to the patient's clinical condition.

End of Topic: Deep Vein Thrombosis (DVT)
Revise Virchow's triad, the two-level Wells score, D-dimer limitations, compression ultrasound, anticoagulant monitoring and emergency recognition of pulmonary embolism. Complete the 25-question interactive test.